331 related articles for article (PubMed ID: 17095209)
21. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
[TBL] [Abstract][Full Text] [Related]
24. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa.
Toma S; Canavese G; Grimaldi A; Ravera G; Ugolini D; Percivale P; Badellino F
Oncol Rep; 2003; 10(3):641-7. PubMed ID: 12684637
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
[TBL] [Abstract][Full Text] [Related]
26. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verweij J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S180-4. PubMed ID: 8453694
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
29. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
Schlemmer M; Reichardt P; Verweij J; Hartmann JT; Judson I; Thyss A; Hogendoorn PC; Marreaud S; Van Glabbeke M; Blay JY
Eur J Cancer; 2008 Nov; 44(16):2433-6. PubMed ID: 18771914
[TBL] [Abstract][Full Text] [Related]
32. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
33. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
Bisogno G; Ferrari A; Bergeron C; Scagnellato A; Prete A; Alaggio R; Casanova M; D'Angelo P; Di Cataldo A; Carli M
Cancer; 2005 Apr; 103(8):1719-24. PubMed ID: 15754335
[TBL] [Abstract][Full Text] [Related]
34. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
Siehl JM; Thiel E; Schmittel A; Hütter G; Deckert PM; Szelényi H; Keilholz U
Cancer; 2005 Aug; 104(3):611-7. PubMed ID: 15968689
[TBL] [Abstract][Full Text] [Related]
35. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
[TBL] [Abstract][Full Text] [Related]
36. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
